NCT07066098View on ClinicalTrials.gov

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

PHASE3RecruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Pancreatic Cancer
Interventions
DRUG

IBI343

Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle

DRUG

Placebo

Subjects in the control arm will receive placebo 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle

Trial Locations (1)

201321

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07066098 - A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) | Biotech Hunter | Biotech Hunter